NCT03841266View on ClinicalTrials.gov

Recurrence Risk Evaluation by 21-gene Detection

CompletedOBSERVATIONAL

Enrollment

220

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 20, 2019

Study Completion Date

February 1, 2019

Conditions

Relationship and Consistency Analysis

Interventions

DIAGNOSTIC_TEST

recurrence risk evaluation

Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.

Trial Locations (1)

710032

Xijing hoapital, Xi'an

All Listed Sponsors

lead

Xijing Hospital

OTHER

NCT03841266 - Recurrence Risk Evaluation by 21-gene Detection | Biotech Hunter | Biotech Hunter